Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension.

Autor: Simon MA; Division of Cardiology, Department of Medicine University of California San Francisco California USA., Hanrott K; Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK., Budd DC; Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK., Torres F; UT Southwestern Medical Center Dallas Texas USA., Grünig E; Centre for Pulmonary Hypertension Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital Heidelberg Germany., Escribano-Subias P; CIBER-CV Cardiology Department, Pulmonary Hypertension Unit Hospital Universitario 12 de Octubre Madrid Spain., Meseguer ML; Lung Transplant and Pulmonary Vascular Diseases Department Hospital Universitari Vall d'Hebron Barcelona Spain., Halank M; Department of Internal Medicine I University Hospital Carl Gustav Carus Dresden Germany., Opitz C; Department of Cardiology DRK Kliniken Berlin Germany.; Department of Cardiology, University Heart Center Berlin Charité University Medicine Berlin Germany., Hall DA; Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK., Hewens D; Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK., Powley WM; Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK., Siederer S; Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK., Bayliffe A; Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK.; Marengo Therapeutics and Apple Tree Partners Cambridge Massachusetts USA., Lazaar AL; Discovery Medicine, Clinical Pharmacology and Experimental Medicine GlaxoSmithKline plc. Collegeville Pennsylvania USA., Cahn A; Research and Development, Medicines Research Centre GlaxoSmithKline plc. Stevenage UK., Rosenkranz S; Department III of Internal Medicine, Cologne Cardiovascular Research Center (CCRC) Cologne University Heart Center Cologne Germany.

Publikováno v: Pulmonary circulation [Pulm Circ] 2022 Jan 20; Vol. 12 (1), pp. e12024. Date of Electronic Publication: 2022 Jan 20 (Print Publication: 2022).

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.

Autor: Khan A; Div. of Pulmonary & Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA., Benthin C; Div. of Pulmonary & Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA., Zeno B; Riverside Methodist Hospital, Columbus, OH, USA., Albertson TE; School of Medicine, University of California, Davis, Sacramento, CA, USA., Boyd J; St. Paul's Hospital, Vancouver, BC, Canada., Christie JD; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Hall R; Nova Scotia Health Authority and Dalhousie University, Halifax, NS, Canada., Poirier G; Charles LeMoyne Hospital, Sherbrooke University, Greenfield Park, QC, Canada., Ronco JJ; Critical Care Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada., Tidswell M; Division of Pulmonary and Critical Care, Department of Medicine, Baystate Medical Center, Springfield, MA, USA., Hardes K; GlaxoSmithKline R&D, Stockley Park, UK., Powley WM; GlaxoSmithKline R&D, Stevenage, UK., Wright TJ; GlaxoSmithKline R&D, Stevenage, UK., Siederer SK; GlaxoSmithKline R&D, Stevenage, UK., Fairman DA; GlaxoSmithKline R&D, Stevenage, UK., Lipson DA; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.; GlaxoSmithKline R&D, King of Prussia, PA, USA., Bayliffe AI; GlaxoSmithKline R&D, Stevenage, UK., Lazaar AL; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. aili.l.lazaar@gsk.com.; GlaxoSmithKline R&D, King of Prussia, PA, USA. aili.l.lazaar@gsk.com.

Publikováno v: Critical care (London, England) [Crit Care] 2017 Sep 07; Vol. 21 (1), pp. 234. Date of Electronic Publication: 2017 Sep 07.

A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.

Autor: Christie JD; 1Pulmonary and Critical Care Medicine, University of Pennsylvania School of Medicine, Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA. 2Department of Surgery, Duke University Medical Center, Durham, NC. 3Department of Surgery, University of Kentucky, Lexington, KY. 4Division of Trauma and Surgical Critical Care, Vanderbilt University Medical Center, Nashville, TN. 5Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. 6GlaxoSmithKline, Stockley Park, UK. 7GlaxoSmithKline, Stevenage, UK. 8GlaxoSmithKline, King of Prussia, PA., Vaslef S, Chang PK, May AK, Gunn SR, Yang S, Hardes K, Kahl L, Powley WM, Lipson DA, Bayliffe AI, Lazaar AL

Publikováno v: Critical care medicine [Crit Care Med] 2015 Sep; Vol. 43 (9), pp. 1859-69.